Narrow search
Showing 101 - 110 of 48,634
Cover Image
Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension: Economic Evaluation of Ramipril Efficacy In Nephropathy (REIN) Study for Germany from the...
Schadlich, Peter K.; Brecht, Josef Georg; Brunetti, Massimo - In: PharmacoEconomics 19 (2001) 5, pp. 497-512
Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). Objective: To determine the additional cost per patient-year of chronic...
Persistent link: https://www.econbiz.de/10005590520
Cover Image
Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma
Sheth, Ketan; Borker, Rohit; Emmett, Amanda; Rickard, … - In: PharmacoEconomics 20 (2002) 13, pp. 909-918
Objective: To compare the relative cost effectiveness of salmeterol (50mug)/ fluticasone propionate (100mug) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone. Study design: A...
Persistent link: https://www.econbiz.de/10005590542
Cover Image
Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process
Dimasi, Joseph A.; Caglarcan, Erol; Wood-Armany, Maria - In: PharmacoEconomics 19 (2001) 7, pp. 753-766
Objectives: This study examines the organisational structure of pharmacoeconomics departments in major pharmaceutical and biotechnology companies, the impediments to optimal use of pharmacoeconomic evaluations by companies and the integration of pharmacoeconomic analysis with research and...
Persistent link: https://www.econbiz.de/10005449023
Cover Image
Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada
Iskedjian, Michael; Einarson, Thomas R.; O'Brien, Bernie J. - In: PharmacoEconomics 19 (2001) 5, pp. 551-563
Objective: Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic...
Persistent link: https://www.econbiz.de/10005449092
Cover Image
Effectiveness of Eletriptan in Reducing Time Loss Caused by Migraine Attacks
Wells, Nicholas E.J.; Steiner, Timothy J. - In: PharmacoEconomics 18 (2000) 6, pp. 557-566
Background: The growing literature on the economics of migraine and its treatment generally indicates that the direct healthcare costs of managing the disorder are relatively low compared with the personal and societal burdens resulting from the disruption to normal functioning caused by...
Persistent link: https://www.econbiz.de/10005449270
Cover Image
Economic Impact of Low Dose Polyethylene Glycol 3350 Plus Electrolytes Compared with Lactulose in the Management of Idiopathic Constipation in the UK
Christie, Angela H.; Culbert, Pearl; Guest, Julian F. - In: PharmacoEconomics 20 (2002) 1, pp. 49-60
Objective: To estimate the economic impact of using low dose polyethyene glycol 3350 (PEG 3350) plus electrolytes (PEG+E) compared with lactulose in the treatment of idiopathic constipation in ambulant patients. Design and perspective: This was a decision analytic modelling study performed from...
Persistent link: https://www.econbiz.de/10005404796
Cover Image
Economic Burden of Irritable Bowel Syndrome: Proposed Strategies to Control Expenditures
Camilleri, Michael; Williams, Donald E. - In: PharmacoEconomics 17 (2000) 4, pp. 331-338
It has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in the 8 most industrialised countries. This paper reviews the data on calculations of direct costs. The true economic burden is unclear, as there are insufficient data on indirect...
Persistent link: https://www.econbiz.de/10005590450
Cover Image
Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
Kauf, Teresa L.; Farkouh, Raymond A.; Earnshaw, Stephanie R. - In: PharmacoEconomics 28 (2010) 11, pp. 1025-1039
Background: Abacavir sulfate (abacavir) is associated with a hypersensitivity reaction (HSR) that affects 5-8% of … patients. While serious complications are rare, failure to identify it, or abacavir re-challenge following HSR, can be fatal … prior to abacavir initiation (intrinsic value of screening) was evaluated using a 60-day decision-tree model. Next, the …
Persistent link: https://www.econbiz.de/10008677585
Cover Image
US Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial...
Brogan, Anita; Mauskopf, Josephine; Talbird, Sandra E.; … - In: PharmacoEconomics 28 (2010) S1, pp. 129-146
Introduction: The phase III TITAN trial evaluated the use of darunavir with low-dose ritonavir (DRV/r) 600/100 mg twice … daily (bid) compared with lopinavir with low-dose ritonavir (LPV/r) in treatment-experienced, lopinavir-naive patients. This …
Persistent link: https://www.econbiz.de/10010614305
Cover Image
Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
Moeremans, Karen; Annemans, Lieven; Lothgren, Mickael … - In: PharmacoEconomics 28 (2010) S1, pp. 107-128
-dose ritonavir (DRV/r) provides significant clinical benefit compared with control protease inhibitors (PIs) in highly treatment …
Persistent link: https://www.econbiz.de/10010614309